<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T13:07:26Z</responseDate>
  <request identifier="oai:figshare.com:article/33718960" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33718960</identifier>
        <datestamp>2026-09-14T05:40:24Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Supplementary file 1_Disease-modifying therapies are associated with improved olfactory function via NK cell- microbiota interactions in multiple sclerosis.doc</dc:title>
          <dc:creator>Zhuoma Danzhen (24868363)</dc:creator>
          <dc:creator>Zhang Yang (532183)</dc:creator>
          <dc:creator>Lan Chu (8665008)</dc:creator>
          <dc:creator>Zidan Gao (24868366)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>disease-modifying therapies (DMTs)</dc:subject>
          <dc:subject>lymphocyte subsets</dc:subject>
          <dc:subject>multiple sclerosis</dc:subject>
          <dc:subject>olfactory</dc:subject>
          <dc:subject>university of pennsylvania smell identification test (UPSIT)</dc:subject>
          <dc:description>Objective&lt;p&gt;To examine the associations of nasal microbiota with disease-modifying therapies (DMTs), lymphocyte subsets and olfactory function in multiple sclerosis (MS).&lt;/p&gt;Methods&lt;p&gt;Thirty patients with MS and 30 age- and sex-matched healthy controls (HCs) were enrolled. Patients were classified as DMT-treated (MS[DMT+]) or untreated (MS[DMT-]). Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). Lymphocyte subsets were measured by flow cytometry, and nasal microbiota were analysed by 16S rRNA sequencing.&lt;/p&gt;Results&lt;p&gt;Olfactory function was lower in MS than in HCs, and better in MS(DMTs+) than in MS(DMTs−) (p =0.016, 95% CI 0.5614 to 4.941). NK cell counts were lower in MS(DMTs+) than in MS(DMTs−) (p =0.049, 95% CI -244.7 to -0.2109). And NK cell counts in MS(DMTs+) correlate with UPSIT (r =-0.527, p =0.029). Compared with HCs, MS(DMTs−) showed higher Shannon diversity (p =0.038), increased Proteobacteria (p =0.004), reduced Moraxellaceae (p =0.037) and Enterobacteriaceae (p =0.033), and enriched branched-chain amino acid biosynthesis (p =0.026). In MS(DMTs+), Campylobacter, Anaerococcus, Peptoniphilus, Prevotella, and Finegoldia were positively correlated with circulating NK cells (all p&lt;0.05).&lt;/p&gt;Conclusion&lt;p&gt;DMTs may improve olfactory function in MS, possibly through modulation of circulating NK cell-associated immune status and nasal microbiota, in addition to controlling disease-related inflammation.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-14T05:40:24Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1889149.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Supplementary_file_1_Disease-modifying_therapies_are_associated_with_improved_olfactory_function_via_NK_cell-_microbiota_interactions_in_multiple_sclerosis_doc/33718960</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
